CLEARBRIDGE HEALTH LIMITED
(Incorporated in the Republic of Singapore)
(Company Registration No. 201001436C)

UPDATE ON LEGAL PROCEEDINGS AGAINST FORMER DIRECTORS OF AN INDIRECT SUBSIDIARY IN INDONESIA

The Board of Directors of Clearbridge Health Limited (the "**Company**" and together with its subsidiaries, the "**Group**") refers to the announcements dated 10 June 2020 (the "**10 June 2020 Announcement**") and 16 June 2020 (the "**16 June 2020 Announcement**", and together with the 10 June 2020 Announcement, the "**Announcements**") relating to the legal proceedings (the "**Suit**") commenced by the Company's indirect subsidiary, PT Tirta Medika Jaya ("**TMJ**") in the District Court of South Jakarta (the "**Court**") against its former directors Sam Pranoto, Andreas Kuntjoro Mukri and David Sahputra Hadiwibowo (collectively, the "**Defendants**"). Unless otherwise defined, capitalised terms in this announcement shall have the same meaning as ascribed to them in the Announcements.

The Group wishes to announce that at a hearing held on 8 March 2022 in relation to the Suit, the Court gave oral judgment in favour of TMJ for the reasons that it has been proven that the Defendants have committed an unlawful act due to their failure to carry out their fiduciary duties in their management of TMJ. In this regard, with reference to the claims sought by TMJ (as set out in the 10 June 2020 Announcement), the Court ordered that, among others (the "**Court's Decision**"):

(a) the Suit that has been filed by TMJ be accepted and partially granted;

(b) a declaration be made that the Defendants have committed unlawful acts;

(c) the Defendants be ordered to jointly pay damages to TMJ for the Pecuniary Losses amounting to approximately IDR15.19 billion (approximately S$1.44 million) (**"Judgment Sum"**). The Court did not order the Defendants to pay non-pecuniary losses suffered by TMJ amounting to approximately IDR2.00 trillion (approximately S$189.18 million);

(d) no declaration be made for the seizure of certain movable assets and/or immovable assets of the Defendants as security for costs;

(e) no declaration be made that the verdict of this case be carried out immediately;

(f) the Defendants be ordered to pay the court fees according to applicable law amounting to IDR2.72 million (approximately S$257); and

(g) no order be made for the Defendants to make a public apology to TMJ in Singapore and Indonesia.

The Defendants may submit an appeal within 14 days from 8 March 2022 (inclusive).

The Group and its legal advisors will update its shareholders if there are any further material developments on this matter. In the meantime, the operations at TMJ are unaffected by the Suit and the Court's Decision. The Suit and the Court's Decision may have a material favourable impact on the financial performance of the Group for the current financial year ending 31 December 2022 ("**FY2022**") given the amount of the Judgment Sum and, depending on, among others, whether the Judgment Sum or part thereof will be paid in FY2022 or otherwise and whether the Defendants appeal against the Court's Decision and the outcome of any such appeal.

Shareholders and potential investors are reminded to exercise caution when dealing in the securities of the Company and should consult their stockbrokers, bank managers, solicitors, accountants or other professional advisers if they are in doubt about the actions that they should take.

BY ORDER OF THE BOARD

YEE PINH JEREMY
Executive Director and Chief Executive Officer

9 March 2022

The SGD equivalent of the IDR figures in this announcement have been arrived at based on an exchange rate of IDR 10,571.94 : SGD 1.00 as at 7 March 2022.

---

*This announcement has been prepared by the Company and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the "**Sponsor**"), for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited ("**SGX-ST**") Listing Manual Section B: Rules of Catalist. This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Mr David Tham, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.*